Zheng Quan Shi Bao Wang·2026-01-14 01:06Company Overview - Zeling Bio has submitted a listing application to the Hong Kong Stock Exchange, with joint sponsors Jefferies and CICC [1] - The company is a late-stage clinical biotechnology firm focused on integrating structural biology, artificial intelligence, and clinically relevant disease models to develop highly differentiated small molecule therapies [1] - Zeling Bio targets significant unmet medical needs in hematologic diseases, oncology, central nervous system disorders, and immune/inflammatory diseases, possessing eight proprietary assets in clinical and preclinical stages [1] Product Pipeline - The core product, Fluorotinib (FM), is in Phase 3 registration clinical trials for the treatment of myelofibrosis, a type of myeloproliferative neoplasm [1] - FM is a novel triple-target inhibitor of Janus kinase 2, FMS-like tyrosine kinase 3, and cyclin-dependent kinase 6 [1] - Another product, Pidilizumab (PM), is also in Phase 3 registration clinical trials for the treatment of relapsed/refractory diffuse large B-cell lymphoma, designed as a next-generation selective HDAC I/IIb inhibitor emphasizing selectivity and safety [1] Industry Insights - The global oncology therapeutics market is projected to grow from $262.1 billion in 2024 to $724.9 billion by 2035 [2] - The Chinese oncology therapeutics market is expected to expand from $37.2 billion in 2024 to $143.7 billion by 2035 [2] - The global myelofibrosis therapeutics market is anticipated to increase from $3 billion in 2024 to $11.1 billion by 2035, with a compound annual growth rate of 14.6% expected in the Chinese market during the same period [2]